Category: Dermatological

TNF inhibitors - an update from ‘best practice’ November 2009 Tumour necrosis factor (TNF) inhibitors are used in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, severe psoriasis, Crohn’s disease and juvenile idiopathic arthritis, when conventional treatments have failed. TNF inhibitors are associated with some serious adverse effects and use should be closely monitored.
Correspondence from ‘best practice’ September 2009 Alternative to flucloxacilin for impetigo?
Managing eczema from ‘best practice’ September 2009 Eczema can have a significant impact on the lives of patients and their families. The aims of treatment are to identify and minimise exposure to irritants, maintain the barrier function of the skin using emollients and use anti-inflammatory treatment to control exacerbations.
Practice tips from ‘best practice’ September 2009 All about PPIs, Fire hazard with paraffin
Quiz feedback: How to treat acne from ‘best practice’ September 2009 Feedback on the acne quiz from BPJ 20
The treatment of psoriasis in primary care from ‘best practice’ September 2009 Psoriasis is an emotionally and physically debilitating disease which can significantly affect quality of life. Support with psychosocial factors and advice on lifestyle interventions is important. Topical treatments are first choice for mild psoriasis. Systemic treatments are used for severe symptoms and are usually initiated in secondary care.
Topical corticosteroid treatment for skin conditions from ‘best practice’ September 2009 Topical corticosteroids are used to treat many skin conditions. They should be used at the lowest potency possible for the shortest amount of time to gain control of symptoms.
Correspondence from ‘best practice’ June 2009 Management of impetigo CVD and Antioxidants Erratum - STI testing report
Correspondence from ‘best practice’ April 2009 Are fish oil supplements recommended during pregnancy? CVD and cholesterol